Elena Eldridge
Psychiatric/Mental Health · Valrico, FLNPI 1588938989
Payments from drug & device makers
Across 199 payments — averaging $44.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$981
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$884
- Axsome Therapeutics, Inc.$850
- Alkermes, Inc.$749
- Vanda Pharmaceuticals Inc.$591
- plus $3K from 13 others
What the payments were for
- Food & beverage$8,812100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $1,697 |
| Otsuka America Pharmaceutical, Inc. | 21 | $981 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $884 |
| Axsome Therapeutics, Inc. | 19 | $850 |
| Alkermes, Inc. | 12 | $749 |
| Vanda Pharmaceuticals Inc. | 10 | $591 |
| Johnson & Johnson | 12 | $561 |
| Teva Pharmaceuticals USA, Inc. | 9 | $472 |
| Neurocrine Biosciences, Inc. | 9 | $397 |
| Tris Pharma Inc | 20 | $276 |
| Lundbeck LLC | 2 | $265 |
| Almatica Pharma LLC | 10 | $192 |
| Supernus Pharmaceuticals, Inc. | 5 | $184 |
| Collegium Pharmaceutical, Inc. | 2 | $141 |
| E.r. Squibb & Sons, L.L.C. | 3 | $139 |
| Merck | 7 | $135 |
| Alpha Cognition USA, Inc. | 1 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $97 |
| Sanofi Pasteur Inc. | 1 | $96 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,450
- VRAYLAR$1,231
- LYBALVI$1,071
- REXULTI$761
- CAPLYTA$587
- Auvelity$581
- Fanapt$369
- Zunveyl$311
- SPRAVATO$272
- Austedo XR$247
- INGREZZA$244
- ARISTADA INITIO$238
- ABILIFY ASIMTUFII$147
- ABILIFY MAINTENA$147
- JORNAY PM$125
- UZEDY$123
- QELBREE$119
How this compares
$8,812 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 17 | $210 |
| Benztropine Mesylate | 11 | $120 |
| Clonazepam | 11 | $114 |
| Trazodone Hcl | 15 | $48 |
| Sertraline Hcl | 11 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $192 | $3911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Valrico
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.